# Tesalys

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tesalys

- Industry: Power & Utilities
- Headquarters: Toulouse, France
- Website: www.tesalys.fr
- Total disclosed funding: $5.3M
- Latest round: Series B (Sep 22, 2019)
- Investors on record: 3

## About

Tesalys SAS is a French company specializing in the management of infectious medical waste through innovative steam sterilization technology, ensuring safe and environmentally responsible waste treatment.Founded in 2012, Tesalys SAS is headquartered in Toulouse, France, focusing on the development of solutions for infectious waste management. The company has executed 5 deals, with its most recent funding round being a Series B on September 22, 2019, where it raised EUR 4 million from IXO Private Equity and Sigma Gestion. The founder's history is not publicly detailed, and there are no known subsidiaries or parent companies.Tesalys specializes in the management of infectious medical waste, particularly through its core product offerings, STERIPLUS™ and STERISHRED®. These systems function by grinding and decontaminating hazardous waste using steam sterilization at 135°C, providing an efficient, environmentally friendly solution for on-site treatment of infectious waste. The technology is designed to mitigate risks associated with the storage, transport, and disposal of biohazardous materials generated in hospitals and laboratories. Tesalys serves a diverse client base that includes hospitals, clinics, and laboratory facilities in over 67 countries worldwide. Their products cater specifically to markets with stringent health regulations and high volumes of medical waste, emphasizing the company's commitment to public health and environmental sustainability.Tesalys generates revenue through direct sales of its STERIPLUS™ and STERISHRED® systems, along with associated maintenance and training services. The company engages in business-to-business transactions, providing these solutions to healthcare institutions that require effective management of infectious waste. Revenue streams include initial equipment sales, ongoing service contracts for maintenance, and training sessions for operators, ensuring that clients are proficient in the use of the systems. The structured sales process often involves partnerships with authorized distributors who facilitate installations and training. Tesalys' focus on providing high-quality, reliable products reinforces its value proposition in the healthcare waste management sector.Tesalys plans to leverage its recent Series B funding of EUR 4 million raised in September 2019 to enhance its product offerings and expand into new geographical markets. The company is actively developing the next generation of its waste management solutions and aims to launch these products by 2023. Furthermore, Tesalys is targeting expansion into markets in Asia and North America, where there is an increasing demand for effective medical waste management solutions.

## Funding rounds

- Series B, Sep 22, 2019, $4.4M — IXO Private Equity, Trail Capital
- Series A, Jul 18, 2014, $0.9M — Entrepreneur Invest

## Investors

- Entrepreneur Invest (https://capitalatlas.ai/funds/entrepreneur-invest) — Series A
- IXO Private Equity (https://capitalatlas.ai/funds/ixo-private-equity) — Series B
- Trail Capital (https://capitalatlas.ai/funds/trail-capital) — Series B